Mesalamine Rectal (mesalamine) NDC 69918-560

NDC codes

FDA NDC Directory

Product NDC (as listed)69918-560Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69918-0560Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69918-560-30	69918056030	30 SUPPOSITORY in 1 BOX (69918-560-30)Marketed from Jun 24, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mesalamine Rectal
Generic name (nonproprietary): mesalamine
Active ingredients: Mesalamine — 1000 mg/1
Dosage form: Suppository
Route: Rectal
Labeler: Amring Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208362
Marketing start: Jun 24, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Aminosalicylic Acids (Chemical structure)
Identifiers: Product ID 69918-560_795356f9-9817-4b51-8de6-4504a2a48abdSPL ID 795356f9-9817-4b51-8de6-4504a2a48abdSPL set ID 87de237c-febb-42ca-b2a4-b444396f8640RxCUI 248420UNII 4Q81I59GXC
Pharmacologic class: Aminosalicylate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N469918056030 followed by a unit qualifier and the quantity

Package 69918-0560-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 15, 2023.

Indications (excerpt from the label)

1. INDICATIONS AND USAGE Mesalamine Rectal Suppositories are indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. Mesalamine Rectal Suppositories are an aminosalicylate indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)